Keyword: Biogen

Biogen HQ

Flip-flop: Aducanumab

A few weeks ago, Biogen and Eisai’s Alzheimer’s disease candidate aducanumab would have been right at the top of the list of failed 2019 trials. But that would have been before the surprise announcement that the project hadn’t been canned after all.